ELYSIUM THERAPEUTICS, INC. — Department of Health and Human Services SBIR Phase I: DESCRIPTION: Elysium has discovered a novel molecular deactivation (XpiRx or expiring pi
ELYSIUM THERAPEUTICS, INC. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $224,737
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- DA14-013
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
DESCRIPTION: Elysium has discovered a novel molecular deactivation (XpiRx or expiring pill ) technology that is designed to effectively curb the widespread abuse and diversion of unused prescription opioid drugs. Using Elysium's technology, opioid drug products will safely, and irreversibly lose their potency over a specified time window beyond the prescribed use period, rendering them devoid of opioid agonist effects, and, therefore, completely abuse-resistant. Our XpiRx technology enables: (i) effectivepain relief during the prescribed use period; (ii) abuse-resistance via non-oral routes; (iii) oral abuse-deterrence beyond the prescribed use period; and (iv) oral overdose protection beyond the programmed expiration date. According to President Obama,Prescription drug abuse is America's fastest-growing drug problem, and one largely fed by an unlikely source - Americans' medicine cabinets. Over 70% of abusers obtain unused prescription opioids from their friends and family. Current opioid pills lose on